The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Novel Blood Test Could Transform Multiple Myeloma Diagnosis, Monitoring
Carfilzomib‐Based Quadruplets Challenge VRd as Frontline Multiple Myeloma Backbone
Model Based on EHR Parameters Can Predict 5-Year Multiple Myeloma Risk
How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community
Outpatient Models Boost Cost-Effectiveness of CAR T and Bispecific Therapy in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP
Leveraging MRD Testing to Advance Value-Based Care in Multiple Myeloma: Emilie Aschenbrenner, PharmD, BCOP
Balancing Cost, Coverage, and Clinical Value in First-Line Multiple Myeloma Care: Emilie Aschenbrenner, PharmD, BCOP
CEPHEUS Trial Data Reinforce DVRd as New Standard for Multiple Myeloma: Saad Z. Usmani, MD, MBA
Emerging Multiple Myeloma Data and Future Outlook From ASCO 2025
Integrating CAR T-Cell Therapy and Bispecific Antibodies Into Hematologic Malignancy Care: Anita D’Souza, MD
Safety Should Always Be a Priority With CAR T for Multiple Myeloma: Surbhi Sidana, MD, MBBS
Advancing First-Line Therapy for Multiple Myeloma: Updates From IsKia and IMROZ Trials
PERSEUS and ADVANCE Updates: Evolving Approaches to MRD-Driven Myeloma Care
Linvoseltamab Approval Expands Access, Increases Competition in BCMA Bispecifics Space: Sundar Jagannath, MBBS
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Closing Gaps in CLL Care: Managed Care Insights and Strategies
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens